A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Running, not enrolling · Phase 1 · Has a placebo group

Conditions studied: Asthma

In brief

The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.

Key facts

Study ID
NCT06637371
Run by
Amgen
People needed
21
Starts
2024-10-16
Expected to finish
2027-04-10
Last updated by the study team
2026-06-17

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.